There is very little data on early immune response to viral infection in humans. So excited that our paper on early responses now on PubMed https://t.co/RT55Ne0T43
Peng et al. find that immunodominant CTLs specific for NP105-113-B*07:02 are associated with reduced COVID-19 severity. NP105-113-B*07:02-specific CTLs show potent anti-viral functionality and may represent rational T cell vaccine targets. @TaoDongGroup https://t.co/pwqE4eZBAB